

Vixtimotamab

Cat. No.:	HY-P99958
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) ^[1] .								
IC₅₀ & Target	KD: 0.3 nM (CD33, HL-60 cells), 5.1 nM (CD3, Human T cells) ^[1]								
In Vitro	<p>Vixtimotamab (TandAb T564; 24 h) induces CD25 and CD69 with EC₅₀s of 1 pM and 2 pM, respectively^[1]. Vixtimotamab (TandAb T564; 4 days) induces T-cell proliferation in PBMCs with an EC₅₀ of 3 pM^[1]. Vixtimotamab (TandAb T564; 25 pM, 48 h) shows cytotoxicity against HL-60 and KG-1a cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HL-60 and KG-1a cells</td> </tr> <tr> <td>Concentration:</td> <td>25 pM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Showed cytotoxicity of 86.0±1.4% and 81.3±1.5% against HL-60 and KG-1a cells, respectively.</td> </tr> </table>	Cell Line:	HL-60 and KG-1a cells	Concentration:	25 pM	Incubation Time:	48 h	Result:	Showed cytotoxicity of 86.0±1.4% and 81.3±1.5% against HL-60 and KG-1a cells, respectively.
Cell Line:	HL-60 and KG-1a cells								
Concentration:	25 pM								
Incubation Time:	48 h								
Result:	Showed cytotoxicity of 86.0±1.4% and 81.3±1.5% against HL-60 and KG-1a cells, respectively.								
In Vivo	<p>Vixtimotamab (TandAb T564; 0.1-10 µg/mouse, i.v.; 5 days) demonstrates dose-dependent tumor growth delay in a prophylactic HL-60 graft NOD/scid mouse model^[1]. Vixtimotamab (TandAb T564; 50 µg/mouse/d, i.v.; 7 days) substantially inhibits tumor growth in an established HL-60 xenograft NOD/scid mouse model^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>8-week-old NOD/scid female mice, weighing 20.7 ± 1.48 g, prophylactic HL-60 graft model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.1, 1, or 10 µg/mouse</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection, on days 0, 1, 2, 3, and 4</td> </tr> </table>	Animal Model:	8-week-old NOD/scid female mice, weighing 20.7 ± 1.48 g, prophylactic HL-60 graft model ^[1]	Dosage:	0.1, 1, or 10 µg/mouse	Administration:	Intravenous injection, on days 0, 1, 2, 3, and 4		
Animal Model:	8-week-old NOD/scid female mice, weighing 20.7 ± 1.48 g, prophylactic HL-60 graft model ^[1]								
Dosage:	0.1, 1, or 10 µg/mouse								
Administration:	Intravenous injection, on days 0, 1, 2, 3, and 4								

Result:	Demonstrated dose-dependent tumor growth delay.
---------	---

REFERENCES

[1]. Reusch U, et al. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res. 2016 Dec 1;22(23):5829-5838.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA